INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $131 | +35.1% | 2,518 | +64.9% | 0.10% | +33.8% |
| Q2 2023 | $97 | -26.5% | 1,527 | -37.2% | 0.07% | -35.7% |
| Q1 2023 | $132 | -40.5% | 2,433 | -42.0% | 0.12% | +26.4% |
| Q4 2022 | $222 | -99.7% | 4,194 | +122.1% | 0.09% | +16.7% |
| Q3 2022 | $88,000 | +700.0% | 1,888 | +898.9% | 0.08% | +766.7% |
| Q2 2022 | $11,000 | +1000.0% | 189 | +1475.0% | 0.01% | +800.0% |
| Q1 2022 | $1,000 | 0.0% | 12 | -20.0% | 0.00% | 0.0% |
| Q4 2021 | $1,000 | – | 15 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |